In the Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial, vitE (800 IU for 96 weeks) effectively decreased levels of ALT and AST, and induced significant improvements in NASH histopathology [33]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.